b27pd
Trade name: Optiquel
Peptideexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01195948)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- HLA class I histocompatibility antigen, B alpha chainImmunity, desensitized
HLA-B immunity, desensitized
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- b27pd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01195948 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2010 | National Eye Institute (NEI), The EMMES Corporation |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Eye Institute (NEI) | Government | 1 | 1 | 1 | 2010 |
| The EMMES Corporation | For profit | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1